X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs GLENMARK PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA GLENMARK PHARMA SANOFI INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 29.9 13.7 219.3% View Chart
P/BV x 5.3 3.8 138.2% View Chart
Dividend Yield % 1.7 0.3 513.8%  

Financials

 SANOFI INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
GLENMARK PHARMA
Mar-16
SANOFI INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs4,5601,262 361.3%   
Low Rs4,400672 655.2%   
Sales per share (Unadj.) Rs1,028.5270.6 380.1%  
Earnings per share (Unadj.) Rs129.024.9 518.4%  
Cash flow per share (Unadj.) Rs186.034.4 540.4%  
Dividends per share (Unadj.) Rs68.002.00 3,400.0%  
Dividend yield (eoy) %1.50.2 733.7%  
Book value per share (Unadj.) Rs753.6151.3 498.0%  
Shares outstanding (eoy) m23.03282.16 8.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.43.6 121.9%   
Avg P/E ratio x34.738.9 89.4%  
P/CF ratio (eoy) x24.128.1 85.8%  
Price / Book Value ratio x5.96.4 93.1%  
Dividend payout %52.78.0 655.8%   
Avg Mkt Cap Rs m103,174272,778 37.8%   
No. of employees `0003.610.0 36.1%   
Total wages/salary Rs m3,59213,782 26.1%   
Avg. sales/employee Rs Th6,537.77,614.9 85.9%   
Avg. wages/employee Rs Th991.41,374.8 72.1%   
Avg. net profit/employee Rs Th819.8700.2 117.1%   
INCOME DATA
Net Sales Rs m23,68676,340 31.0%  
Other income Rs m708356 198.8%   
Total revenues Rs m24,39476,696 31.8%   
Gross profit Rs m5,28114,172 37.3%  
Depreciation Rs m1,3132,691 48.8%   
Interest Rs m151,789 0.8%   
Profit before tax Rs m4,66110,048 46.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6913,028 55.8%   
Profit after tax Rs m2,9707,019 42.3%  
Gross profit margin %22.318.6 120.1%  
Effective tax rate %36.330.1 120.4%   
Net profit margin %12.59.2 136.4%  
BALANCE SHEET DATA
Current assets Rs m15,67359,096 26.5%   
Current liabilities Rs m6,67840,018 16.7%   
Net working cap to sales %38.025.0 152.0%  
Current ratio x2.31.5 158.9%  
Inventory Days Days7675 101.4%  
Debtors Days Days22119 18.7%  
Net fixed assets Rs m8,09839,075 20.7%   
Share capital Rs m230282 81.6%   
"Free" reserves Rs m17,08830,281 56.4%   
Net worth Rs m17,35642,703 40.6%   
Long term debt Rs m024,873 0.0%   
Total assets Rs m25,400111,026 22.9%  
Interest coverage x311.76.6 4,711.4%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.7 135.6%   
Return on assets %11.87.9 148.1%  
Return on equity %17.116.4 104.1%  
Return on capital %26.917.5 153.8%  
Exports to sales %24.543.3 56.6%   
Imports to sales %28.07.4 376.5%   
Exports (fob) Rs m5,80133,044 17.6%   
Imports (cif) Rs m6,6275,672 116.8%   
Fx inflow Rs m7,14536,945 19.3%   
Fx outflow Rs m6,84661,066 11.2%   
Net fx Rs m299-24,122 -1.2%   
CASH FLOW
From Operations Rs m3,2263,449 93.5%  
From Investments Rs m-1,555-8,802 17.7%  
From Financial Activity Rs m-1,8186,986 -26.0%  
Net Cashflow Rs m-147934 -15.7%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 6.9 208.7%  
FIIs % 14.6 34.4 42.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.5 100.0%  
Shareholders   15,184 56,727 26.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   VENUS REMEDIES  ORCHID PHARMA LTD  PFIZER  J.B.CHEMICALS  SHASUN PHARMA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Pharma Stocks Among Top Gainers(01:30 pm)

After opening the day in green, share markets in India witnessed choppy trades and are presently trading marginally above the dotted line.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 22, 2017 02:53 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS